NEUROPHARMACOLOGY OF COGNITION AND MOOD IN GERIATRIC NEUROPSYCHIATRY

老年神经精神病学中认知和情绪的神经药理学

• 批准号: 3968425
• 负责人: T SUNDERLAND
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF MENTAL HEALTH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3968425
• 关键词: Alzheimer's disease; MAO inhibitors; aging; anticholinergic agent; anxiety; arecoline; behavior test; cholinergic agents; depression; dosage; human old age (65+); human subject; memory disorders; naloxone; neuropharmacology; neuropsychological tests; nicotine; opiate alkaloid; psychobiology; psychopharmacology; scopolamine

Previous work from this unit has focused on the cognitive and behavioral responses of Alzheimer patients to pharmacologic challenges with cholinergic and opiate antagonists. We observed that the dementia patients appeared more sensitive to these antagonists (scopolamine and naloxone) than previously reported in younger controls. This year, we have demonstrated that behavioral and cognitive responses (but not physiologic changes) following scopolamine are indeed greater at lower doses in Alzheimer patients than in age-matched controls, suggesting increased sensitivity in this population with known cholinergic deficits. We are now in the process of completing a similar comparison using naloxone in age-matched normal volunteers. Expanded studies of the cognitive, behavioral and neuroendocrine responses of Alzheimer patients to cholinergic agonists such as arecholine and nicotine are also underway.

该单元的先前工作重点是认知和行为 阿尔茨海默氏症患者对药理挑战的反应 胆碱能和鸦片拮抗剂。 我们观察到痴呆症患者 似乎对这些拮抗剂（Scopolamine和Naloxone）更敏感 比以前在年轻对照中报道的。 今年，我们有 证明了行为和认知反应（但没有生理 在较低剂量下，scopolamine的变化确实更大 阿尔茨海默氏症患者比年龄匹配的对照组中的患者增加 该人群的敏感性，患有已知胆碱能缺陷。 我们现在 在使用纳洛酮完成类似比较的过程中 年龄匹配的正常志愿者。 对认知的扩展研究， 阿尔茨海默氏症患者对行为和神经内分泌反应 胆碱能激动剂（如丁乙啉和尼古丁）也正在进行中。